

BLOOD HURST & O'REARDON, LLP

1 BLOOD HURST & O'REARDON, LLP  
2 TIMOTHY G. BLOOD (149343)  
3 THOMAS J. O'REARDON II (247952)  
4 701 B Street, Suite 1700  
5 San Diego, CA 92101  
6 Telephone: 619/338-1100  
7 619/338-1101 (fax)  
8 tblood@bholaw.com  
9 toreardon@bholaw.com

6 CARPENTER LAW GROUP  
7 TODD D. CARPENTER (234464)  
8 402 West Broadway, 29th Floor  
9 San Diego, California 92101  
10 Telephone: 619/347-3517  
11 619/756-6991 (fax)  
12 todd@carpenterlawyers.com

10 Attorneys for Plaintiff and the Class

11 **UNITED STATES DISTRICT COURT**  
12 **SOUTHERN DISTRICT OF CALIFORNIA**

13 ROBERT DORFMAN, On Behalf of  
14 Himself and All Others Similarly  
15 Situated,

15 Plaintiff,

16 v.

17 NUTRAMAX LABORATORIES,  
18 INC. WAL-MART STORES, INC.,  
19 and RITE-AID CORPORATION,

20 Defendants.

Case No.: '13CV0873 WQHRBB

CLASS ACTION

CLASS ACTION COMPLAINT FOR:

1. VIOLATION OF CONSUMERS LEGAL REMEDIES ACT, CIVIL CODE §1750 *et seq.*;
2. VIOLATION OF THE UNFAIR COMPETITION LAW, BUSINESS AND PROFESSIONS CODE §17200 *et seq.*; and
3. BREACH OF EXPRESS WARRANTY.

DEMAND FOR JURY TRIAL

Case No.

CLASS ACTION COMPLAINT

BLOOD HURST & O'REARDON, LLP

1 Plaintiff Robert Dorfman brings this action on behalf of himself and all  
2 others similarly situated against Defendant Nutramax Laboratories, Inc.  
3 (“Nutramax”), Wal-Mart Stores, Inc., and Rite-Aid Corporation (collectively  
4 “Defendants”) and states:

5 **NATURE OF ACTION**

6 1. Defendants distribute, market and sell Nutramax’s “Cosamin” line  
7 of glucosamine-based products marketed as “Joint Health Supplements.”  
8 Defendants claim Cosamin provides a variety of significant health benefits for  
9 the cartilage and joints of all consumers who ingest Cosamin. These claimed  
10 health benefits are the only reason a consumer would purchase Cosamin.  
11 Defendants’ advertising claims, however, are false, misleading, and reasonably  
12 likely to deceive the public.

13 2. Defendants represent that the primary active ingredients in its  
14 Cosamin products are “glucosamine,” and “chondroitin sulfate.” Through an  
15 extensive and uniform nationwide advertising campaign, Defendants represent  
16 that Cosamin “is the only brand proven effective in controlled, published U.S.  
17 studies to reduce joint pain,” and that it has been “[s]hown in laboratory tests to  
18 protect cartilage cells from breakdown.” See Product Label, Cosamin DS  
19 attached hereto as Exhibit “A”. Defendants further warrant that the product  
20 “works better” and “lasts longer” purportedly than other similar competitor  
21 products.

22 3. All available scientific evidence demonstrates that the Cosamin  
23 products have no efficacy at all, are ineffective in the improvement of joint  
24 health, and provide no benefits related to the reduction of pain in human joints or  
25 protecting cartilage from breakdown. In fact, Defendants do not have any  
26 competent, reliable scientific evidence that substantiates their representations  
27 about the health benefits of consuming Cosamin. Numerous scientifically valid  
28 studies have been conducted on the ingredients, including the core or primary

1 ingredient in Cosamin, glucosamine hydrochloride, and they have universally  
2 demonstrated that glucosamine and glucosamine in combination with other  
3 ingredients such as chondroitin and chondroitin sulfate have absolutely no  
4 scientific value in the treatment of joint pain or discomfort.

5 4. Defendants represent that the active ingredients in Cosamin  
6 products provide relief for joint pain and osteoarthritis. The product labeling  
7 states, that it will “protect your cartilage” and “reduce joint pain”. *See* product  
8 label, attached as Exhibit “A”. These bold claims are in addition to other  
9 misrepresentations claiming that it is the only brand “proven effective in  
10 controlled, published U.S. studies to reduce joint pain.” Defendants also  
11 represent throughout the Cosamin advertising that Cosamin is the “#1 brand  
12 recommended by Orthopedic Specialists,” implying that there is legitimate  
13 science substantiating the joint health and cartilage marketing claims.

14 5. Defendants convey their uniform, deceptive message to consumers  
15 through a variety of media including their websites and online promotional  
16 materials, and, most important, at the point of purchase, on the front of the  
17 Products’ packaging/labeling where it cannot be missed by consumers. The front  
18 of the Cosamin product label states in bold print, “Protect your cartilage with the  
19 only brand proven to reduce joint pain.” The only reason a consumer would  
20 purchase Cosamin is to obtain the advertised joint-health benefits, which the  
21 Cosamin products do not provide.

22 6. As a result of Defendants’ deceptive advertising and false claims  
23 regarding the efficacy of the Cosamin product, Plaintiff and the proposed class  
24 have purchased a product which does not perform as represented and they have  
25 been harmed in the amount they paid for the product, which, in the case of  
26 Plaintiff Dorman is approximately thirty five dollars.

27 7. Plaintiff brings this action on behalf of himself and other similarly  
28 situated consumers who have purchased the Cosamin products to halt the

1 dissemination of this false, misleading and deceptive advertising message,  
 2 correct the false and misleading perception it has created in the minds of  
 3 consumers, and obtain redress for those who have purchased the Cosamin  
 4 products. Based on violations of state unfair competition laws and Defendant's  
 5 breach of express warranty, Plaintiff seeks injunctive and monetary relief for  
 6 consumers who purchased the Cosamin products.

### 7 **JURISDICTION AND VENUE**

8 8. This Court has original jurisdiction pursuant to 28 U.S.C.  
 9 §1332(d)(2). The matter in controversy, exclusive of interest and costs, exceeds  
 10 the sum or value of \$5,000,000 and is a class action in which there are in excess  
 11 of 100 class members and many members of the Class are citizens of a state  
 12 different from Defendants.

13 9. This Court has personal jurisdiction over Defendants because  
 14 Defendants are authorized to conduct and do conduct business in California.  
 15 Defendants have marketed, promoted, distributed, and sold the Cosamin product  
 16 in California and Defendants have sufficient minimum contacts with this State  
 17 and/or sufficiently avail themselves of the markets in this State through its  
 18 promotion, sales, distribution and marketing within this State to render the  
 19 exercise of jurisdiction by this Court permissible.

20 10. Venue is proper in this Court pursuant to 28 U.S.C. §§1391(a) and  
 21 (b) because a substantial part of the events or omissions giving rise to Plaintiff's  
 22 claims occurred while he resided in this judicial district. Venue is also proper  
 23 under 18 U.S.C. §1965(a) because Defendants transact substantial business in  
 24 this District.

### 25 **PARTIES**

26 11. Plaintiff Robert Dorfman resides in San Diego County, California.  
 27 In or around October of 2012, Plaintiff was exposed to and saw the  
 28 representations described herein regarding the joint health benefits of Cosamin

1 DS by reading the Cosamin DS product label in a Rite-Aid store near his home in  
2 Del Mar, California. Thereafter, Plaintiff was again exposed to and saw the  
3 representations described herein regarding the joint health benefits of Cosamin  
4 DS by reading the Cosamin DS product label in a Wal-Mart store located in San  
5 Diego, California. In reliance on the claims listed on the product label described  
6 herein and above, and specifically those claims listed on the front of the product  
7 label, that Cosamin would, “protect his cartilage” and “reduce his joint pain,”  
8 Plaintiff purchased the Cosamin DS product at a Rite-Aid store located near his  
9 home in Del Mar, California, and at a Wal-Mart located at 4840 Shawline Street,  
10 San Diego, California 92111. He paid approximately \$35.00 for the product at  
11 Rite-Aid. He paid approximately \$25.00 for the product at Wal-Mart. On each  
12 occasion, Mr. Dorfman purchased the product believing it would provide the  
13 advertised joint health benefits and improve his joint soreness and comfort. As a  
14 result of his purchase, Plaintiff suffered injury in fact and lost money. Had  
15 Plaintiff known the truth about Defendants’ misrepresentations and omissions, he  
16 would not have purchased the Cosamin DS product. Plaintiff Dorfman is not  
17 claiming physical harm or seeking the recovery of personal injury damages.

18 12. Defendant Nutramax Laboratories, Inc. is incorporated under the  
19 laws of the state of Maryland. Nutramax’s corporate headquarters is located at  
20 2208 Lakeside Boulevard, Edgewood, Maryland 21040. Nutramax researches,  
21 develops, manufactures, distributes, markets and sells nutritional supplements  
22 products across the United States and internationally. Nutramax marketed and  
23 sold the Cosamin products to tens of thousands of consumers in California.

24 13. Defendant Rite-Aid Corporation (“Rite-Aid”) is one of the nation’s  
25 largest drugstore chains with more than 4,600 stores in 31 states and the District  
26 of Columbia. Rite-Aid is a Delaware corporation headquartered in Camp Hill,  
27 Pennsylvania. During the Class period, Rite-Aid promoted, marketed and sold  
28 the Cosamin products throughout the United States and in the State of California.

1           14. Defendant Wal-Mart Stores, Inc. (“Wal-Mart”) is one of the world’s  
 2 largest retailers. Wal-Mart operates Wal-Mart Discount Stores, Wal-Mart  
 3 Supercenters, Sam’s Club warehouse stores, Neighborhood Markets,  
 4 walmartstores.com, and walmart.com. Wal-Mart is a Delaware corporation with  
 5 its principal executive offices in Bentonville, Arkansas. During the Class period,  
 6 Wal-Mart promoted, marketed and sold the Cosamin products throughout the  
 7 United States and in the State of California.

## 8                           **FACTUAL ALLEGATIONS**

### 9                                   *The Cosamin Products*

10           15. Nutramax manufactures, distributes, and sells the Cosamin line of  
 11 dietary supplements. Those products include Cosamin DS and Cosamin ASU.  
 12 Nutramax began manufacturing, marketing and selling the Cosamin products in  
 13 1992.

14           16. The Cosamin products are sold in virtually every major food, drug,  
 15 and mass retail outlet in the country and online retailers, including, but not  
 16 limited to: Wal-Mart, BJ’s Wholesale Club, CVS, Kroger, and Rite-Aid. The  
 17 Cosamin products are also sold through online retailers such as walmart.com,  
 18 riteaid.com costco.com, cvs.com, and walgreens.com.

19           17. Since the Cosamin products’ launch, Nutramax has consistently  
 20 conveyed the message to consumers throughout California that the Cosamin  
 21 products, with their “exclusive formula” will reduce joint pain and protect joint  
 22 cartilage of all persons who ingest Cosamin. These claims false and misleading,  
 23 and are not substantiated by competent scientific evidence.

24           18. The Wal-Mart and Rite-Aid defendants market and sell the Cosamin  
 25 products at issue, and participated in the dissemination of the representations  
 26 concerning the efficacy of the Cosamin products and adopted the representations  
 27 as their own. The Wal-Mart and Rite-Aid defendants entered into marketing and  
 28 sales agreements with Nutramax to further promote and repeat the false and

1 deceptive statements at issue. By placing the Cosamin products on their store  
2 shelves and on retail websites, and thereafter advertising and selling the Products  
3 to Plaintiff and other members of the Class, the Wal-Mart and Rite-Aid  
4 defendants adopted, and are responsible for, the representations Nutramax made  
5 on packaging regarding the efficacy of the Cosamin products.

6 19. The Wal-Mart and Rite-Aid defendants also promote, market and  
7 sell their own Wal-Mart and Rite-Aid-branded glucosamine chondroitin  
8 products, which they market for joint health.<sup>1</sup>

9 20. The primary active ingredient in all the Cosamin products is  
10 glucosamine hydrochloride. Glucosamine is an amino sugar that the body  
11 produces and distributes in cartilage and other connective tissue. Cosamin DS  
12 and Cosamin ASU also contain chondroitin sulfate. Chondroitin sulfate is a  
13 complex carbohydrate found in the body's connective tissues.

14 21. According to the Mayo Clinic, the signs and symptoms of  
15 osteoarthritis include joint pain, joint tenderness, joint stiffness, and the inability  
16 to move your joint through its full range of motion.<sup>2</sup>

17 22. There is no competent scientific evidence that taking glucosamine  
18 hydrochloride chondroitin sulfate—let alone through oral administration—results  
19 in the body metabolizing it into something that provides the advertised joint

20 <sup>1</sup> <http://shop.riteaid.com/dp/B00009M8K0> (on [www.riteaid.com](http://www.riteaid.com), defendant  
21 promotes Rite Aid Glucosamine/Chondroitin/MSM for “promot[ing] joint  
22 health” – a claim which it repeats on the product’s labeling) (last visited  
23 April 10, 2013); <http://shop.riteaid.com/dp/B001KYVVHQ> (on  
24 [www.riteaid.com](http://www.riteaid.com), defendant promotes Rite Aid Brand Advanced  
25 Glucosamine Chondroitin + MSM for “promot[ing] joint health” – a claim  
26 which it repeats on the product’s labeling) (last visited April 10, 2013);  
27 [http://www.walmart.com/ip/Equate-Glucosamine-Chondroitin-MSM-  
28 Dietary-Supplement-80ct/16767866](http://www.walmart.com/ip/Equate-Glucosamine-Chondroitin-MSM-Dietary-Supplement-80ct/16767866) \* (On [www.walmart.com](http://www.walmart.com), defendant  
promotes its own Equate-branded Glucosamine Chondroitin MSM product,  
which is “specially formulated and may help to renew cartilage, support the  
joints comfortably, and lubricate joints.” Similarly, on the packaging for its  
product, Wal-Mart claims it will “support joint comfort,” and “rebuild  
cartilage and lubricate joints.”) (last visited April 10, 2013).

<sup>2</sup> [http://www.mayoclinic.com/health/osteoarthritis/DS00019/DSECTION=  
symptoms](http://www.mayoclinic.com/health/osteoarthritis/DS00019/DSECTION=symptoms) (last visited April 1, 2013).

BLOOD HURST & O'REARDON, LLP

1 health and cartilage benefits, including relieving the major symptoms of arthritis.

2 23. Cosamin ASU contains Nutramax’s ASU blend, a combination of  
3 avocado/soybean unsaponifiables and soy protein isolate and green tea leaf  
4 extract. There is no competent scientific evidence that taking any of these  
5 ingredients—let alone through oral administration—results in the body  
6 metabolizing them into something that relieves any of the major symptoms of  
7 arthritis.

8 24. Contrary to the stated representations on all the Cosamin products’  
9 labeling and packaging, Defendant does not possess (and has not possessed)  
10 competent scientific evidence that any of these ingredients, taken alone or in  
11 combination, are effective in providing the advertised joint health and cartilage  
12 benefits, including treating the major symptoms of arthritis or any other joint  
13 related ailments.

14 25. Despite scientific studies which demonstrate that the claims are  
15 false and deceptive, and no scientifically valid confirmation that the Cosamin  
16 products are an effective “joint health supplement”—let alone an effective  
17 treatment for *all* joints in the human body, for customers of *all* ages and for *all*  
18 stages of joint disease—Nutramax states on the Cosamin products’ packaging  
19 and labeling that Cosamin is a “Joint Health Supplement” that will “reduce joint  
20 pain” and “protect cartilage cells from breakdown.” Representative Cosamin DS  
21 and Cosamin ASU product packaging and labeling appears as follows:

22 ///


23  
24  
25  
26  
27  
28



BLOOD HURST & O'REARDON, LLP

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

(COSAMIN DS FRONT)



(COSAMIN DS BACK)



BLOOD HURST & O'REARDON, LLP

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28



See also Exhibit A attached (Cosamin product packaging and labeling exemplars containing the false and deceptive statements).

26. Nutramax’s statements on its website repeat and reinforce the false and misleading joint health statements made on the packaging and labeling:

- Shown in laboratory tests to PROTECT CARTILAGE cells from breakdown
- The ONLY brand proven effective in controlled, published U.S. clinical studies to reduce joint pain

BLOOD HURST & O'REARDON, LLP

- 1 • Cosamin DS is the #1 Brand Recommended by Orthopedic Specialists.  
2 As a joint health supplement, Cosamin DS helps reduce joint pain and  
3 stiffness by using ingredients that are safe, effective, and easily  
4 absorbed. Cosamin DS is superior to all other brands and has been  
5 proven effective in published clinical studies.
- 6 • Cosamin is shown effective in peer-reviewed, controlled, published  
7 U.S. research.

8 27. The Cosamin television commercials repeat the same advertising  
9 message. For example, one commercial includes the following statements:

10 Pharmacist Bob Henderson created Cosamin DS – the only glucosamine  
11 chondroitin brand proven to reduce joint pain. Now we’ve added ASU to  
12 make a more advanced formula to combat joint discomfort and cartilage  
13 breakdown. Cosamin – the number one brand recommended by orthopedic  
14 specialists. Anything less just isn’t the best.

15 28. Likewise, in addition to providing pictures of the false and  
16 deceptive packaging and labeling for the Cosamin products, Wal-Mart makes  
17 additional statements on its website that repeat and reinforce the false and  
18 misleading joint health statements made on the packaging and labeling.

19 29. Wal-Mart’s advertising statements about Cosamin DS include:

- 20 • These joint supplements use ingredients that are safe to use and that get  
21 easily absorbed into your bloodstream. The main ingredient being  
22 chondroitin sulfate, these tablets provides cartilage its fluidity and  
23 elasticity. The tablets greatly help in protecting your damaged cartilage,  
24 thereby help reduce stiffness in your joints. These chondroitin sulfate  
25 capsules are easy to swallow. Highly recommended by orthopedic  
26 surgeons and rheumatologists, these capsules help maintain healthy and  
27 pain-free bone joints.
- 28 • Orthopedic surgeon and Rheumatologist recommended

- 1 • Contains the exclusive chondroitin sulfate selected by the National
- 2 Institutes of Health for the GAIT study
- 3 • Take this Cosamin DS Joint Health Supplement to support your joint
- 4 health. These Cosamin DS capsules are the only brand that contains
- 5 pharmaceutical-grade TRH122 chondroitin sulfate and FCHG49
- 6 glucosamine. This is why these glucosamine chondroitin supplements
- 7 from Cosamin DS are a recommended brand from orthopedic surgeons
- 8 and rheumatologists. This joint health supplement isn't only effective,
- 9 but it comes in easy-to-swallow capsules, as well
- 10 • Supports joint health
- 11 • Only brand that contains pharmaceutical-grade TRH122 chondroitin
- 12 sulfate and FCHG49 glucosamine<sup>3</sup>

13 30. Wal-Mart's advertising statements about Cosamin ASU include:

- 14 • The Cosamin ASU Supplement is designed with active people in mind.
- 15 As the number one brand recommended by orthopedic specialists,
- 16 Cosamin ASU Advanced Formula is a comprehensive and complete
- 17 joint support supplement. The joint health supplement has dual synergy
- 18 and triple action. The four capsules in this joint pain supplement
- 19 contain glucosamine and chondroitin sulfate. Start planning for the
- 20 future and for your health by taking this Cosamin ASU Supplement,
- 21 Advanced Formula (90ct).
- 22 • For active people with joint discomfort
- 23 • #1 brand recommended by orthopedic specialists<sup>4</sup>
- 24
- 25

26 3 <http://www.walmart.com/ip/Cosamin-Ds-Exclusive-Formula-Joint-Health-Supplement-60-ct/12556805> (last visited April 10, 2013).

27 4 <http://www.walmart.com/ip/Cosamin-ASU-Joint-Health-Supplement-Advanced-Formula-90ct/15033106?findingMethod=Recommendation:wm:RecentlyViewedItems> (last visited April 10, 2013).

1           31. Likewise, in addition to providing pictures of the false and  
2 deceptive packaging and labeling for the Cosamin products, Rite-Aid makes  
3 additional statements on its website that repeat and reinforce the false and  
4 misleading joint health statements made on the packaging and labeling.

5           32. Rite-Aid's advertising statements about Cosamin DS include:

- 6           • Premium dietary supplement for joint health
- 7           • Joint Health Supplement. Exclusive Formula.
- 8           • Protect your cartilage with the only brand proven to reduce joint pain.
- 9           • The No. 1 brand recommended by orthopedic specialists.
- 10          • Helps your joints last longer.
- 11          • Cosamin DS is recommended by Doctors and Pharmacists for joint  
12 health.
- 13          • The only brand proven effective in controlled, published U.S. studies to  
14 reduce joint pain.
- 15          • Shown in laboratory tests to protect cartilage from breakdown.
- 16          • Contains the full clinical strength of active ingredients-compare to  
17 other brands,
- 18          • Manufactured in the United States following standards practiced by the  
19 pharmaceutical industry.
- 20          • Tested and certified by NSF.
- 21          • The original researched brand.
- 22          • Cosamin DS contains FCHG49 Glucosamine and TRH122 sodium  
23 chondroitin sulfate, Nutramax Laboratories exclusive proprietary  
24 researched specifications.<sup>5</sup>

25          33. Rite-Aid's advertising statements about Cosamin ASU include:

- 26          • Joint Health Supplement.

27  
28          5           http://shop.riteaid.com/dp/B002LL7B5I (last visited April 10, 2013).

- 1 • The No. 1 brand recommended by orthopedic surgeons.
- 2 • Our most potent formula for joint discomfort.
- 3 • Shown to work better than the combination of glucosamine +
- 4 chondroitin sulfate (In laboratory cell culture studies of inflammatory
- 5 markers associated with joint discomfort and cartilage breakdown, it
- 6 was found that the combination of ASU
- 7 [avocado/soybean/unsaponifiables] + glucosamine + chondroitin
- 8 sulfate was better than the combination of glucosamine + chondroitin
- 9 sulfate in reducing these markers).
- 10 • Help your joints last longer.
- 11 • Cosamin ASU is the most complete and comprehensive joint support
- 12 supplement available; is supported by US published research; is
- 13 manufactured in the United States following standards practiced in the
- 14 pharmaceutical industry; contains decaffeinated green tea extract for
- 15 antioxidant health benefits.
- 16 • Tested & certified by NSF.<sup>6</sup>

***Scientific Studies Confirm That Cosamin Is Not Effective And  
Defendants' Health Benefits Message Is False And Deceptive***

19 34. Contrary to the stated representations on all the Products' labeling  
20 and packaging, and throughout Defendants' other advertising and marketing for  
21 the Products, Defendants do not possess (and has not possessed) competent  
22 scientific evidence that any of these ingredients, taken alone or in combination,  
23 are effective in treating the major symptoms of arthritis or any other joint related  
24 ailments.

25 35. Defendants knew or should have known that glucosamine alone and  
26 taken in combination with the other ingredients present in Cosamin have no

27 \_\_\_\_\_  
28 6 <http://shop.riteaid.com/dp/B001CLBA50> (last visited April 10, 2013).

1 actual medicinal value and do not provide any of the warranted benefits as  
2 represented by Defendants' Cosamin products' packaging, labeling and other  
3 advertising. In fact, there is no scientific study demonstrating that any  
4 glucosamine product can regenerate cartilage. To the contrary, as numerous  
5 studies have confirmed, neither glucosamine, chondroitin, nor any other  
6 supplements or ingredients actually regenerate cartilage or provide joint comfort  
7 or relief from pain.

8 36. For example, a 1999 study involving 100 subjects by Houpt *et al.*,  
9 entitled *Effect of glucosamine hydrochloride in the treatment of pain of*  
10 *osteoarthritis of the knee*, 26(11) J. Rheumatol. 2423-30 (1999), found that  
11 glucosamine hydrochloride performed no better than placebo at reducing pain at  
12 the conclusion of the eight week trial.

13 37. In February 2004, a Supplement to the American Journal of  
14 Orthopedics published an article entitled "*Restoring Articular Cartilage in the*  
15 *Knee.*" The authors concluded that adult cartilage cannot be regenerated because  
16 it is not vascularized, meaning that blood does not flow to damaged cartilage  
17 which prevents any mechanism for regeneration.

18 38. Likewise, a 2004 study by McAlindon, *et al.*, entitled, *Effectiveness*  
19 *of Glucosamine For Symptoms of Knee Osteoarthritis: Results From and*  
20 *Internet-Based Randomized Double-Blind Controlled Trial*, 117(9) Am. J. Med.  
21 649-9 (Nov. 2004), concluded that "glucosamine was no more effective than  
22 placebo in treating symptoms of knee osteoarthritis" – in short, that glucosamine  
23 is ineffective. *Id.* at 646 ("we found no difference between the glucosamine and  
24 placebo groups in any of the outcome measures, at any of the assessment time  
25 points").

26 39. A 2004 study by Cibere, *et al.*, entitled, "*Randomized, Double-*  
27 *Blind, Placebo-Controlled Glucosamine Discontinuation Trial In Knee*  
28 *Osteoarthritis*", 51(5) Arthritis Care & Research 738-45 (Oct. 15, 2004), studied

1 users of glucosamine who had claimed to have experienced at least moderate  
2 improvement after starting glucosamine. These patients were divided into two  
3 groups - one that continued using glucosamine and one that was given a placebo.  
4 For six months, the primary outcome observed was the proportion of disease  
5 flares in the glucosamine and placebo groups. A secondary outcome was the  
6 time to disease flare. The study results reflected that there were no differences in  
7 either the primary or secondary outcomes for glucosamine and placebo. The  
8 authors concluded that the study provided no evidence of symptomatic benefit  
9 from continued use of glucosamine - in other words, any prior perceived benefits  
10 were due to the placebo effect and not glucosamine. *Id.* at 743 (“In this study,  
11 we found that knee OA disease flare occurred as frequently, as quickly, and as  
12 severely in patients who were randomized to continue receiving glucosamine  
13 compared with those who received placebo. As a result, the efficacy of  
14 glucosamine as a symptom-modifying drug in knee OA is not supported by our  
15 study.”).

16 40. A large (1,583 subjects), 24-week, multi-center RCT study  
17 sponsored by the National Institute of Health (“NIH”), published in the New  
18 England Journal of Medicine (the “2006 GAIT Study”), concluded: “[t]he  
19 analysis of the primary outcome measure did not show that either [glucosamine  
20 or chondroitin], alone or in combination, was efficacious. . . .” Clegg, D., *et al.*,  
21 Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee  
22 Osteoarthritis, 354 New England J. of Med. 795, 806 (2006).

23 41. The 2006 GAIT Study authors rigorously evaluated the  
24 effectiveness of glucosamine hydrochloride and chondroitin, alone and in  
25 combination, on osteoarthritis for six months. According to the study's authors,  
26 “[t]he analysis of the primary outcome measure did not show that either  
27 supplement, alone or in combination, was efficacious. . . .” 2006 GAIT Study at  
28 806.



1           42. Subsequent GAIT studies in 2008 and 2010 reported that  
2 glucosamine and chondroitin did not rebuild cartilage and were otherwise  
3 ineffective – even in patients with moderate to severe knee pain for which the  
4 2006 reported results were inconclusive. *See* Sawitzke, A.D., *et al.*, *The Effect*  
5 *of Glucosamine and/or Chondroitin Sulfate on the Progression of Knee*  
6 *Osteoarthritis: A GAIT Report*, 58(10) *J. Arthritis Rheum.* 3183-91 (Oct. 2008);  
7 Sawitzke, A.D., *Clinical Efficacy And Safety Of Glucosamine, Chondroitin*  
8 *Sulphate, Their Combination, Celecoxib Or Placebo Taken To Treat*  
9 *Osteoarthritis Of The Knee: 2 Year Results From GAIT*, 69(8) *Ann Rhem. Dis.*  
10 1459-64 (Aug. 2010).

11           43. The GAIT studies are consistent with the reported results of prior  
12 and subsequent studies. For example, the National Collaborating Centre for  
13 Chronic Conditions (“NCCCC”) reported “the evidence to support the efficacy  
14 of glucosamine hydrochloride as a symptom modifier is poor” and the “evidence  
15 for efficacy of chondroitin was less convincing.” NCCCC, *Osteoarthritis*  
16 *National Clinical Guideline for Care and Management of Adults*, Royal College  
17 of Physicians, London 2008. Consistent with its lack of efficacy findings, the  
18 NCCCC Guideline did not recommend the use of glucosamine or chondroitin for  
19 treating osteoarthritis. *Id.* at 33.

20           44. In a 2007 report, Vlad, *et al.* reviewed all studies involving  
21 glucosamine hydrochloride and concluded that “[g]lucosamine hydrochloride is  
22 not effective.” *Glucosamine for Pain in Osteoarthritis*, 56:7 *Arthritis Rheum.*  
23 2267-77 (2007); *see also id.* at 2275 (“we believe that there is sufficient  
24 information to conclude that glucosamine hydrochloride lacks efficacy for pain  
25 in OA”).

26           45. In October 2008, the American College of Rheumatology's *Journal*,  
27 *Arthritis & Rheumatism* published a report on a double blind study conducted at  
28 multiple centers in the United States examining joint space width loss with

1 radiograph films in patients who were treated with glucosamine hydrochloride.  
2 The authors concluded that after two years of treatment with this supplement, the  
3 treatment did not demonstrate a clinically important difference in joint space  
4 width loss. Sawitzke *et al.*, Glucosamine for Pain in Osteoarthritis: Why do Trial  
5 Results Differ?, *Arthritis Rheum.*, 58:3183-3191 (2008).

6 46. In December 2008, the American Academy of Orthopaedic  
7 Surgeons published clinical practice guidelines for the “Treatment of  
8 Osteoarthritis of the Knee (Non-Arthroplasty),” and recommended that  
9 “glucosamine and sulfate or hydrochloride should not be prescribed for patients  
10 with symptomatic OA of the knee.” Richmond *et al.*, *Treatment of osteoarthritis*  
11 *of the knee* (nonarthroplasty), *J. Am. Acad. Orthop. Surg.* Vol. 17 No. 9 591-600  
12 (2009). This recommendation was based on a 2007 report from the Agency for  
13 Healthcare Research and Quality (AHRQ), which states that “the best available  
14 evidence found that glucosamine hydrochloride, chondroitin sulfate, or their  
15 combination did not have any clinical benefit in patients with primary OA of the  
16 knee.” Samson, *et al.*, *Treatment of Primary and Secondary Osteoarthritis of the*  
17 *Knee, Agency for Healthcare Research and Quality*, 2007 Sep 1. Report No. 157.

18 47. Even studies not concerning the type of glucosamine in the Cosamin  
19 Products demonstrate that glucosamine does not provide the joint health benefits  
20 that Defendants represent. For example, a study by Rozendaal, *et al.*, entitled,  
21 *Effect of Glucosamine Sulfate on Hip Osteoarthritis*, 148 *Ann. of Intern. Med.*  
22 268-77 (2008), assessing the effectiveness of glucosamine on the symptoms and  
23 structural progression of hip osteoarthritis during two years of treatment,  
24 concluded that glucosamine was no better than placebo in reducing symptoms  
25 and progression of hip osteoarthritis.

26 48. In March 2009, Harvard Medical School published a study  
27 conclusively proving that the ingestion of glucosamine could not affect the  
28 growth of cartilage. The study took note of the foregoing 2006 and 2008 studies,

1 which “cast considerable doubt” upon the value of glucosamine. The authors  
2 went on to conduct an independent study of subjects ingesting 1500 mg of  
3 glucosamine, and proved that *only trace amounts of glucosamine* entered the  
4 human serum, far below any amount that could possibly affect cartilage  
5 (emphasis added). Moreover, even those trace amounts were present only for a  
6 few hours after ingestion. The authors noted that a 1986 study had found no  
7 glucosamine in human plasma after ingestion of four times the usual 1500 mg of  
8 glucosamine chloride or sulphate. Silbert, Dietary Glucosamine Under Question,  
9 *Glycobiology* 19(6):564-567 (2009).

10 49. In April 2009, the Journal of Orthopedic Surgery published an  
11 article entitled, “*Review Article: Glucosamine.*” The article's authors concluded  
12 that, based on their literature review, there was “little or no evidence” to suggest  
13 that glucosamine was superior to a placebo even in slowing down cartilage  
14 deterioration, much less regenerating it. Kirkham, *et al.*, Review Article:  
15 Glucosamine, *Journal of Orthopedic Surgery*, 17(1): 72-6 (2009).

16 50. In 2009, a panel of scientists from the European Food Safety  
17 Authority (“EFSA”) (a panel established by the European Union to provide  
18 independent scientific advice to improve food safety and consumer protection),  
19 reviewed nineteen studies submitted by an applicant, and concluded that “a cause  
20 and effect relationship has not been established between the consumption of  
21 glucosamine hydrochloride and a reduced rate of cartilage degeneration in  
22 individuals without osteoarthritis.” EFSA Panel on Dietetic Products, Nutrition  
23 and Allergies, *Scientific Opinion on the substantiation of a health claim related*  
24 *to glucosamine hydrochloride and reduced rate of cartilage degeneration and*  
25 *reduced risk of osteoarthritis*, *EFSA Journal* (2009), 7(10):1358.

26 51. In a separate opinion from 2009, an EFSA panel examined the  
27 evidence for glucosamine (either hydrochloride or sulfate) alone or in  
28 combination with chondroitin sulfate and maintenance of joints. The claimed

1 effect was “joint health,” and the proposed claims included “helps to maintain  
2 healthy joint,” “supports mobility,” and “helps to keep joints supple and  
3 flexible.” Based on its review of eleven human intervention studies, three meta-  
4 analyses, 21 reviews and background papers, two animal studies, one in vitro  
5 study, one short report, and one case report, the EFSA panel concluded that “a  
6 cause and effect relationship has not been established between the consumption  
7 of glucosamine (either as glucosamine hydrochloride or as glucosamine  
8 sulphate), either alone or in combination with chondroitin sulphate, and the  
9 maintenance of normal joints.” EFSA Panel on Dietetic Products, Nutrition and  
10 Allergies, Scientific Opinion on the substantiation of health claims related to  
11 glucosamine alone or in combination with chondroitin sulphate and maintenance  
12 of joints and reduction of inflammation, EFSA Journal (2009), 7(9):1264.

13 52. A 2010 meta-analysis by Wandel, *et al.*, entitled *Effects of*  
14 *Glucosamine, Chondroitin, Or Placebo In Patients With Osteoarthritis Of Hip*  
15 *Or Knee: Network Meta- Analysis*, BMJ 341:c4675 (2010), examined prior  
16 studies involving glucosamine and chondroitin, alone or in combination, and  
17 whether they relieved the symptoms or progression of arthritis of the knee or hip.  
18 The study authors reported that glucosamine and chondroitin, alone or in  
19 combination, did not reduce joint pain or have an impact on the narrowing of  
20 joint space: “Our findings indicate that glucosamine, chondroitin, and their  
21 combination do not result in a relevant reduction of joint pain nor affect joint  
22 space narrowing compared with placebo.” *Id.* at 8. The authors further  
23 concluded “[w]e believe it unlikely that future trials will show a clinically  
24 relevant benefit of any of the evaluated preparations.” *Id.*

25 53. On July 7, 2010, Wilkens, *et al.*, reported that there was no  
26 difference between placebo and glucosamine for the treatment of low back pain  
27 and lumbar osteoarthritis and that neither glucosamine, nor a placebo, were  
28 effective in reducing pain related disability. The researchers also concluded that,

1 “Based on our results, it seems unwise to recommend glucosamine to all  
2 patients” with low back pain and lumbar osteoarthritis. Wilkens, *et al.*, *Effect of*  
3 *Glucosamine on Pain-Related Disability in Patients With Chronic Low Back*  
4 *Pain and Degenerative Lumbar Osteoarthritis*, 304(1) JAMA 45-52 (July 7,  
5 2010).

6 54. In 2011, Miller and Clegg, after surveying the clinical study history  
7 of glucosamine and chondroitin, concluded that, “[t]he cost-effectiveness of  
8 these dietary supplements alone or in combination in the treatment of OA has not  
9 been demonstrated in North America.” Miller, K. and Clegg, D., *Glucosamine*  
10 *and Chondroitin Sulfate*, *Rheum. Dis. Clin. N. Am.* 37 103-118 (2011).

11 55. In June 2011, the Journal of Pharmacy & Pharmaceutical Sciences  
12 published an article entitled, “*The Glucosamine Controversy; A Pharmacokinetic*  
13 *Issue.*” The authors concluded that regardless of the formulation used, no or  
14 marginal beneficial effects were observed as a result of low glucosamine  
15 bioavailability. Aghazadeh-Habashi and Jamali, *The Glucosamine Controversy;*  
16 *A Pharmacokinetic Issue*, *Journal of Pharmacy & Pharmaceutical Sciences*,  
17 14(2): 264-273 (2011).

18 56. In 2012, a report by Rovati, *et al.* entitled *Crystalline glucosamine*  
19 *sulfate in the management of knee osteoarthritis: efficacy, safety, and*  
20 *pharmacokinetic properties*, *Ther Adv Musculoskel Dis* 4(3) 167-180, noted that  
21 glucosamine hydrochloride “ha[s] never been shown to be effective.”

22 57. In 2012, EFSA examined the evidence to determine if glucosamine  
23 sulphate or glucosamine hydrochloride could substantiate a claimed effect of  
24 “contributes to the maintenance of normal joint cartilage.” Based on its review  
25 of 61 references provided by Merck Consumer Healthcare, the EFSA panel  
26 concluded that “a cause and effect relationship has not been established between  
27 the consumption of glucosamine and maintenance of normal joint cartilage in  
28 individuals without osteoarthritis.” EFSA Panel on Dietetic Products, Nutrition

1 and Allergies, *Scientific Opinion on the substantiation of a health claim related*  
 2 *to glucosamine and maintenance of normal joint cartilage*, EFSA Journal 2012,  
 3 10(5): 2691.

4 58. The studies identified by Nutramax on its website are fundamentally  
 5 flawed, not scientifically valid and/or possess obvious, unmitigated bias, *i.e.* the  
 6 study itself was sponsored by Nutramax. For example:

7 **Cosamin ASU research & review articles**

8 (as identified on Nutramax's website:

9 [http://www.nutramaxlabs.com/index.php/2012-06-20-17-18-09/research-](http://www.nutramaxlabs.com/index.php/2012-06-20-17-18-09/research-citations)  
 10 [citations](http://www.nutramaxlabs.com/index.php/2012-06-20-17-18-09/research-citations)) (Last viewed 04/08/2013).

- 11 • Au RY, Al-Talib TK, Au AY, *et al.*, *Osteoarthritis and Cartilage*  
 12 2007;15(11):1249-1255.

13 This study was conducted with the support of two employees of Defendant  
 14 Nutramax, and did not involve any formulation of glucosamine, nor  
 15 chondroitin. Instead, it studied the effect of avocado soybean  
 unsaponifiables on human cells in a laboratory.

- 16 • Au R, Au A, Rashmir-Raven A, Frondoza CG. *The FASEB Journal*  
 17 2007;21(6):A736.

18 This study was “supported by Nutramax Laboratories, and at least one  
 19 employees of Nutramax contributed to its findings. The study was  
 20 conducted on Horse and Human cells in a laboratory, and the findings  
 21 were totally unreliable, and conclusive at best: “Our study supports the  
 22 ***potential*** clinical utility of the combination of ASU, Glu, and CS in  
 suppressing inflammation.” (emphasis added).

- 23 • Au A, Au R, Kramer E, *et al.*, *The FASEB Journal* 2007;21(6):A736.

24 This Study was not performed on any on either of the key ingredients,  
 25 glucosamine or chondroitin sulfate.

- 26 • Au AY, Polotsky M, Au RY, *et al.*, *Proceedings, 35th Annual Conference*  
 27 *Veterinary Orthopedic Society* 2008,56.

28 This was a conference; not a clinical study.

## 1           **Cosamin DS Clinical Trials**

- 2           • Das AK, Hammad TA. *Osteoarthritis and Cartilage* 2000;8(5):343-350.

3  
4           This was not an independent clinical trial; it was co-sponsored by  
5           Nutramax Laboratories. Even accounting for the inherent bias in this  
6           study, the WOMAC score, described as a measurement for the “severity of  
7           pain,” did not produce “statistically significant” improvements in pain  
8           reduction amongst the study participants. *Id.* at p. 347.

- 9           • Leffler CT, Philippi AF, Leffler SG, *et al.*, *Military Medicine*  
10           1999;164(2):85-91.

11           This purported “clinical” trial involved only 34 male participants treating  
12           “degenerative joint disease of the knee and low back. The methodology  
13           performed was not scientifically valid as it weighed the participants’  
14           subjective responses and measured improvements in physical activity  
15           (running times). It made no finding regarding benefits for treating spinal  
16           degenerative joint disease.

- 17           • Van Blitterswijk WJ, van de Nes JCM, Wuisman PIJM. *BMC*  
18           *Complementary and Alternative Medicine* 2003, 3:2.

19           This was not clinical trial; it was merely a medical case report of a single  
20           patient who consumed Defendant’s product. The authors reached no  
21           definitive conclusion, stating only, “[I]t is justified to conduct more  
22           definitive trials focusing on (disc) cartilage morphology, to unambiguously  
23           prove or disprove the beneficial affects of these supplements.”

- 24           • Scroggie DA, Albright A, Harris MD. *Archives of Internal Medicine* 2003.  
25           Vol. 163(13): 1587-1590.

26           This study was not designed to test the efficacy of oral glucosamine  
27           consumption, but instead it was designed to determine whether  
28           consumption of glucosamine altered glucose metabolism in patients with  
29           type 2 diabetes.

30           59. To date, there are only two studies, both of which are more than a  
31           decade old and analyze a form of glucosamine not in the Cosamin products,  
32           purporting to claim that the ingestion of glucosamine can affect the growth or  
33           deterioration of cartilage, both sponsored by a glucosamine supplement

1 manufacturer: Pavelka *et al.*, Glucosamine Sulfate Use and Delay of Progression  
2 of Knee Osteoarthritis, *Arch. Intern. Med.*, 162: 2113-2123 (2002); Reginster *et*  
3 *al.*, Long-term Effects of Glucosamine Sulphate On Osteoarthritis Progress: A  
4 Randomised, Placebo-Controlled Clinical Trial, *Lancet*, 357: 251-6 (2001). As  
5 noted in the April 2009 *Journal of Orthopedic Surgery* article, the methodologies  
6 in those studies had “inherently poor reproducibility,” and even minor changes in  
7 posture by the subjects during scans could cause false apparent changes in  
8 cartilage. The authors of the *Journal of Orthopedic Surgery* article explained the  
9 manufacturer-sponsored studies’ findings by noting that “industry-sponsored  
10 trials report positive effects more often than do non-sponsored trials and more  
11 find pro-industry results.” Moreover, neither study examined the form of  
12 glucosamine in the Products – glucosamine hydrochloride. In fact, no reliable  
13 scientific medical study has shown that glucosamine hydrochloride and  
14 chondroitin, alone or in combination, have a structure modifying effect that will  
15 regenerate cartilage that has broken down or worn away.

16 60. Plaintiff and Class members have been and will continue to be  
17 deceived or misled by Defendants’ deceptive representations touting the  
18 effectiveness of the Cosamin products. Plaintiff purchased and used the  
19 Cosamin products during the Class Period and in doing so, read, considered and  
20 based his decisions to buy Cosamin on the above cited label representations.  
21 Because the Cosamin products’ sole purpose is to provide joint relief for the  
22 major symptoms of arthritis, Defendants’ representations and omissions were a  
23 material factor in influencing Plaintiff’s decision to purchase Cosamin. There is  
24 no other reason for Plaintiff to have purchased Cosamin and Plaintiff would not  
25 have purchased Cosamin had he known that Cosamin was ineffective and  
26 Defendants did not possess competent scientific evidence to support the claims  
27 that it made about Cosamin.

28 61. As a result, Plaintiff and the Class members have been damaged in



BLOOD HURST & O'REARDON, LLP

1 their purchases of the Cosamin products and have been deceived into purchasing  
2 products that they believed, based on Defendants' representations, were proven  
3 to be effective in treating the major symptoms of arthritis and other joint related  
4 ailments when, in fact, they are not.

5 62. Defendants, by contrast, reaped enormous profits from their false  
6 marketing and sale of the Cosamin products.

7 **CLASS DEFINITION AND ALLEGATIONS**

8 63. Plaintiff brings this action on behalf of himself and all other  
9 similarly situated pursuant to Rule 23(a), (b)(2), and (b)(3)of the Federal Rules  
10 of Civil Procedure and seeks certification of the following Class:

11 All persons who purchased the Cosamin Products in California.<sup>7</sup>  
12 Excluded from the Class are Defendants, their parents, subsidiaries, affiliates,  
13 officers and directors, those who purchased the Cosamin products for the  
14 purpose of resale, and those who assert claims for personal injury.

15 64. Members of the Class are so numerous and geographically dispersed  
16 that joinder of all Class members is impracticable. Plaintiff is informed and  
17 believes, and on that basis alleges, that the proposed Class contains many  
18 thousands of members. The precise number of Class members is unknown to  
19 Plaintiff.

20 65. Common questions of law and fact exist as to all members of the  
21 Class and predominate over questions affecting only individual Class members.  
22 The common legal and factual questions include, but are not limited to, the  
23 following:

- 24 i. Whether Defendants had competent scientific evidence to  
25 support each of the claims that it made about the Cosamin  
26 products;

27 \_\_\_\_\_  
28 <sup>7</sup> The Cosamin products include: (1) Cosamin DS; and (2)Cosamin ASU.

BLOOD HURST & O'REARDON, LLP

- 1           ii. Whether the claims discussed herein that Defendants made
- 2           about the Cosamin products were or are false, misleading, or
- 3           reasonably likely to deceive;
- 4           iii. Whether Defendants' alleged conduct violates public policy;
- 5           iv. Whether the alleged conduct constitutes violations of the laws
- 6           asserted herein;
- 7           v. Whether Defendants engaged in false and misleading
- 8           advertising;
- 9           vi. Whether Plaintiff and Class members have sustained
- 10          monetary loss and the proper measure of that loss;
- 11          vii. Whether Plaintiff and Class members are entitled to
- 12          restitution, disgorgement of Defendants' profits, declaratory
- 13          and/or injunctive relief; and
- 14          viii. Whether Plaintiff and Class members are entitled to an award
- 15          of compensatory damages.

16           66. The claims asserted by Plaintiff in this action are typical of the  
17 claims of the members of the Class, as the claims arise from the same course of  
18 conduct by Defendants, and the relief sought is common. Plaintiff and Class  
19 members suffered uniform damages caused by their purchase of the Cosamin  
20 products manufactured, marketed, and sold by Defendants.

21           67. Plaintiff will fairly and adequately represent and protect the interests  
22 of the members of the Class. Plaintiff has retained counsel competent and  
23 experienced in both consumer protection and class litigation.

24           68. A class action is superior to other available methods for the fair and  
25 efficient adjudication of this controversy. The expense and burden of individual  
26 litigation would make it impracticable or impossible for proposed Class members  
27 to prosecute their claims individually. It would thus be virtually impossible for  
28 the Class, on an individual basis, to obtain effective redress for the wrongs done

1 to them. Furthermore, even if Class members could afford such individualized  
 2 litigation, the court system could not. Individualized litigation would create the  
 3 danger of inconsistent or contradictory judgments arising from the same set of  
 4 facts. Individualized litigation would also increase the delay and expense to all  
 5 parties and the court system from the issues raised by this action. By contrast,  
 6 the class action device provides the benefits of adjudication of these issues in a  
 7 single proceeding, economies of scale, and comprehensive supervision by a  
 8 single court, and presents no unusual management difficulties under the  
 9 circumstances here.

10 69. In the alternative, the Class also may be certified because  
 11 Defendants have acted or refused to act on grounds generally applicable to the  
 12 Class thereby making final declaratory and/or injunctive relief with respect to the  
 13 members of the Class as a whole appropriate.

#### 14 **COUNT I**

##### 15 **Violation of the Consumers Legal Remedies Act –Civil Code §1750 *et seq.***

16 70. Plaintiff seeks preliminary and permanent injunctive and equitable  
 17 relief on behalf of the entire Class, on grounds generally applicable to the entire  
 18 Class, to enjoin and prevent Defendants from engaging in the acts described, and  
 19 requiring Defendants to provide full restitution to Plaintiff and Class members.

20 71. Unless a Class is certified, Defendants will retain monies that were  
 21 taken from Plaintiff and Class members as a result of their conduct. Unless a  
 22 Class-wide injunction is issued, Defendants will continue to commit the  
 23 violations alleged, and the members of the Class and the general public will  
 24 continue to be misled.

25 72. Plaintiff re-alleges and incorporates by reference the allegations  
 26 contained in the paragraphs above as if fully set forth herein.

27 73. This cause of action is brought under the Consumers Legal  
 28 Remedies Act, California Civil Code §1750, *et seq.* (the “Act”). Plaintiff is a

BLOOD HURST & O'REARDON, LLP

1 consumer as defined by California Civil Code §1761(d). Defendant's Cosamin  
2 products are goods within the meaning of the Act.

3 74. Defendants violated and continues to violate the Act by engaging in  
4 the following practices proscribed by California Civil Code §1770(a) in  
5 transactions with Plaintiff and the Class which were intended to result in, and did  
6 result in, the sale of the Cosamin products:

7 (5) Representing that [the Products] have . . . approval,  
8 characteristics, . . . uses [and] benefits . . . which [they do] not  
9 have . . . .

\* \* \*

10 (7) Representing that [the Products] are of a particular standard, quality  
11 or grade . . . if [they are] of another.

\* \* \*

12 (9) Advertising goods . . . with intent not to sell them as advertised.

\* \* \*

14 (16) Representing that [the Products have] been supplied in accordance  
15 with a previous representation when [they have] not.

16 75. Defendants violated and continue to violate the Act by representing  
17 and failing to disclose material facts on the Cosamin product labels and packages  
18 as described above when they knew, or should have known, that the  
19 representations were unsubstantiated, false and misleading and that the omissions  
20 were of material facts.

21 76. Pursuant to §1782(d) of the Act, Plaintiff and the Class seek a court  
22 order enjoining the above-described wrongful acts and practices of Defendants  
23 and for restitution and disgorgement.

24 77. Pursuant to §1782 of the Act, Plaintiff notified Defendants in  
25 writing by certified mail of the particular violations of §1770 of the Act and  
26 demanded that Defendants rectify the problems associated with the actions  
27 detailed above and give notice to all affected consumers of Defendants' intent to  
28 so act. Copies of the letters are attached hereto as Exhibit B.

BLOOD HURST & O'REARDON, LLP

1 78. If Defendants fail to rectify or agree to rectify the problems  
2 associated with the actions detailed above and give notice to all affected  
3 consumers within 30 days of the date of written notice pursuant to §1782 of the  
4 Act, Plaintiff will amend this complaint to add claims for actual, punitive and  
5 statutory damages, as appropriate.

6 79. Defendants’ conduct is malicious, fraudulent and wanton, and  
7 provides misleading information.

8 80. Pursuant to §1780(d) of the Act, attached hereto as Exhibit C is the  
9 affidavit showing that this action has been commenced in the proper forum.

10 **COUNT II**

11 **Violation of Business & Professions Code §17200, et seq.**

12 81. Plaintiff re-alleges and incorporates by reference the allegations  
13 contained in the paragraphs above as if fully set forth herein.

14 82. As alleged herein, Plaintiff has suffered injury in fact and lost  
15 money or property as a result of Defendants’ conduct because he purchased the  
16 Products.

17 83. In the course of conducting business, Defendants committed  
18 unlawful business practices by, *inter alia*, making the representations (which also  
19 constitute advertising within the meaning of §17200) and omissions of material  
20 facts, as set forth more fully herein, and violating Civil Code §§1572, 1573,  
21 1709, 1711, 1770, Business & Professions Code §§17200, *et seq.*, 17500, *et seq.*,  
22 and the common law.

23 84. Plaintiff and the Class reserve the right to allege other violations of  
24 law, which constitute other unlawful business acts or practices. Such conduct is  
25 ongoing and continues to this date.

26 85. Defendants’ acts, omissions, misrepresentations, practices and non-  
27 disclosures as alleged herein also constitute “unfair” business acts and practices  
28 within the meaning of Business and Professions Code §17200 *et seq.*, in that

BLOOD HURST & O'REARDON, LLP

1 their conduct is substantially injurious to consumers, offends public policy, and  
2 is immoral, unethical, oppressive, and unscrupulous as the gravity of the conduct  
3 outweighs any alleged benefits attributable to such conduct.

4 86. As stated in this complaint, Plaintiff alleges violations of consumer  
5 protection, unfair competition and truth in advertising laws resulting in harm to  
6 consumers. Plaintiff asserts violations of the public policy of engaging in false  
7 and misleading advertising, unfair competition and deceptive conduct towards  
8 consumers. This conduct constitutes violations of the unfair prong of Business &  
9 Professions Code §17200 *et seq.*

10 87. There were reasonably available alternatives to further Defendants'  
11 legitimate business interests, other than the conduct described herein.

12 88. Defendants' claims, nondisclosures and misleading statements, as  
13 more fully set forth above, are also false, misleading and/or likely to deceive the  
14 consuming public within the meaning of Business & Professions Code §17200 *et*  
15 *seq.*

16 89. Defendants' labeling and packaging as described herein, also  
17 constitutes unfair, deceptive, untrue and misleading advertising.

18 90. Defendants' conduct caused and continues to cause substantial  
19 injury to Plaintiff and the other Class members. Plaintiff has suffered injury in  
20 fact and has lost money as a result of Defendants' unfair conduct.

21 91. Plaintiff, on behalf of himself, and all other similarly situated  
22 California residents, seeks restitution of all money obtained from Plaintiff and  
23 the members of the Class collected as a result of unfair competition, an  
24 injunction prohibiting Defendants from continuing such practices, corrective  
25 advertising and all other relief this Court deems appropriate, consistent with  
26 Business & Professions Code §17203.

27  
28

**COUNT III**

### Breach of Express Warranty

92. Plaintiff re-alleges and incorporates by reference the allegations contained in the paragraphs above as if fully set forth herein.

93. Plaintiff, and each member of the Class, formed a contract with Defendants at the time Plaintiff and the other members of the Class purchased the Cosamin products. The terms of that contract include the promises and affirmations of fact made by Defendants on the Cosamin product labels and packages, as described above. These representations constitute express warranties, became part of the basis of the bargain, and are part of a standardized contract between Plaintiff and the members of the Class on the one hand, and Defendants on the other.

94. All conditions precedent to Defendants' liability under this contract have been performed by Plaintiff and the Class.

95. Defendants breached the terms of this contract, including the express warranties, with Plaintiff and the Class by not providing the Cosamin products that could provide the benefits described above which was the only reason Plaintiff and Class members purchased the Cosamin products.

96. As a result of Defendants' breach of warranty, Plaintiff and Class members have been damaged in the amount of the purchase price of the Cosamin products they purchased.

### PRAYER FOR RELIEF

Wherefore, Plaintiff prays for a judgment:

- A. Certifying the class as requested herein;
- B. Awarding Plaintiff and the proposed Class members damages;
- C. Awarding restitution and disgorgement of Defendants' revenues to Plaintiff and the proposed Class members;
- D. Awarding declaratory and injunctive relief as permitted by law or equity, including enjoining Defendants from continuing the

BLOOD HURST & O'REARDON, LLP

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

unlawful practices as set forth herein, and directing Defendants to identify, with court supervision, victims of their conduct and pay them restitution and disgorgement of all monies acquired by Defendants by means of any act or practice declared by this Court to be wrongful;

- E. Ordering Defendants to engage in a corrective advertising campaign;
- F. Awarding attorneys' fees and costs; and
- G. Providing such further relief as may be just and proper.

**JURY DEMAND**

Plaintiff demands a trial by jury on all issues so triable.

Dated: April 11, 2013

BLOOD HURST & O'REARDON, LLP  
TIMOTHY G. BLOOD (149343)  
THOMAS J. O'REARDON II (247952)

By: s/ Timothy G. Blood  
TIMOTHY G. BLOOD

701 B Street, Suite 1700  
San Diego, CA 92101  
Telephone: 619/338-1100  
619/338-1101 (fax)  
tblood@bholaw.com  
toreardon@bholaw.com

CARPENTER LAW GROUP  
TODD D. CARPENTER (CA 234464)  
402 West Broadway, 29th Floor  
San Diego, California 92101  
Telephone: 619/347-3517  
619/756-6991 (fax)  
todd@carpenterlawyers.com

*Attorneys for Plaintiff and the Class*



# EXHIBIT A

**nutramax**  
LABORATORIES, INC.

Maximum Strength •  
**Cosamin<sup>®</sup>ASU**  
JOINT HEALTH SUPPLEMENT

**ADVANCED FORMULA**

*Valuable  
Coupons Inside!*



FCG49<sup>™</sup> Glucosamine  
TRH122<sup>™</sup> Chondroitin Sulfate  
NMX1000<sup>™</sup> ASU

90 Capsules





# Our most potent formula for joint discomfort

**Shown to work better than the combination  
of glucosamine + chondroitin sulfate\***

\*In laboratory cell culture studies of inflammatory markers associated with joint discomfort and cartilage breakdown, it was found that the combination of ASU (avocado soybean unsaponifiables) + glucosamine + chondroitin sulfate was **BETTER** than the combination of glucosamine + chondroitin sulfate in reducing these markers.

**4 CAPSULES CONTAIN:**



\*Source: SIAA, Incorporated Market Research Survey, April 2009  
Survey conducted of Orthopedic Specialists relating to glucosamine  
and chondroitin sulfate brands

# Dual Synergy ♦ Triple Action

## Supplement Facts

Serving Size 4 Capsules

	Amount Per Serving	% Daily Value
Calories	15	
Sodium (as bound to Chondroitin Sulfate)	70 mg	3%*
Total Carbohydrates	1 g	<1%*
Protein	1 g	3%*
High Purity FCHG49® Glucosamine HCl	1500 mg	†
TRH122® Sodium Chondroitin Sulfate (Contains approximately 8% moisture)	800 mg	†
ASU Blend	400 mg	
Avocado/Soybean Unsaponifiables (ASU) Powder▼		†
Green Tea Leaf Extract		†

\*Percent Daily Values are based on a 2,000 calorie diet

†Daily Value Not Established

Ingredients: Glucosamine hydrochloride (crab and shrimp\*\*), sodium chondroitin sulfate, gelatin, proprietary blend (avocado/soybean unsaponifiables, soy protein isolate, tocopherols [preservative], green tea leaf extract, silicon dioxide), gum resin, titanium dioxide, FD&C Yellow No. 5, magnesium stearate, and FD&C Blue No. 1

▼Containing a minimum of 300 mg of ASU powder standardized to contain a minimum of 30% avocado/soybean unsaponifiables

\*\*Derived from crab and shrimp

Some ingredients in this product may be derived from shellfish. This product also contains soy, wheat and gelatin.

Contains 1500 mg of High Purity FCHG49® Glucosamine HCl, 800 mg of TRH122® Sodium Chondroitin Sulfate and 400 mg of ASU Blend. ASU Blend contains Avocado/Soybean Unsaponifiables (ASU) Powder and Green Tea Leaf Extract.

© 2008, All rights reserved. 10/08

# Help your joints last longer

## SUGGESTED USE:

May be taken all at once  
or divided with meals throughout the day

Maximum Protection	4 Capsules per day
Maintenance <small>(Once desired effect is noticed)</small>	Gradually reduce the number of capsules to maintain comfort level.

If you have any condition or allergy that requires medical attention, you should always consult your physician before taking any drug or dietary supplement.

For more information visit [CosaminASU.com](http://CosaminASU.com)  
or call customer service at 1-877-COSAMIN  
(1-877-267-2646).

### Cosamin<sup>®</sup> ASU


- *Is the most complete and comprehensive joint support supplement available.*
- *Is supported by U.S. published research\*.*
- *Is manufactured in the United States following standards practiced in the pharmaceutical industry.*
- *Follows **Tips for the Savvy Supplement User**.  
Visit [FDA.gov](http://FDA.gov).*
- *Contains decaffeinated green tea extract for antioxidant health benefits.*



KEEP OUT OF REACH OF CHILDREN  
KEEP IN A COOL, DRY PLACE

These statements have not been evaluated by the Food & Drug Administration.  
This product is not intended to diagnose, treat, cure or prevent any disease.

Help your joints last longer



THE #1 BRAND RECOMMENDED  
BY ORTHOPEDIC SPECIALISTS\*

Maximum Strength<sup>®</sup>  
**CosaminASU**  
JOINT HEALTH SUPPLEMENT

**ADVANCED FORMULA**

**NITRAMAX**  
LABORATORIES, INC.

Exclusive Formula  
**Cosamin DS**  
100% PURE AND NATURAL

Protect your cartilage with  
the **ONLY BRAND**  
proven to reduce joint pain!

**Valuable  
Coupons Inside!**



Glucosamine HCl  
Chondroitin Sulfate

**100 Capsules**



**COSAMIN DS**

454033

**\$53.99**

## Help your joints last longer

Cosamin<sup>®</sup>DS is recommended by Doctors and Pharmacists for joint health...

- *the only brand proven effective in controlled, published U.S. studies to reduce joint pain*
- *shown in laboratory tests to protect cartilage cells from breakdown*
- *contains the full clinical strength of active ingredients - compare to other brands*
- *manufactured in the United States following standards practiced by the pharmaceutical industry*

For more information on Cosamin DS visit [Cosamin.com](http://Cosamin.com) or call customer service at 1-877-COSAMIN (1-877-267-2646).

KEEP OUT OF REACH OF CHILDREN.  
KEEP IN A COOL, DRY PLACE

\*These statements have not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Psalm 86:12

### Supplement

Serving Size 1 Caplet

#### Calories

#### Sodium

(As Bound to Chondroitin)

#### Vitamin C

(From Manganese Ascorbate)

#### Manganese

(From Manganese Ascorbate)

High Purity PCH-649<sup>®</sup>

Glucosamine HCl

TRH-22<sup>®</sup> Sodium

Chondroitin Sulfate

Contains approximately 200 mg

of each active ingredient per caplet

(Contains 100% of Daily Value)

Ingredients: PCH-649<sup>®</sup>, sodium chondroitin sulfate, water, hydroxyapatite, TRH-22<sup>®</sup>, and PCH-649<sup>®</sup>.



# The original researched brand

## Supplement Facts

Serving Size 1 Capsule

	Amount Per Serving	% Daily Value
Calories	5	
Sodium (as bound to Chondroitin Sulfate)	35 mg	Less than 2%*
Vitamin C (from Manganese Ascorbate)	16 mg	25%*
Manganese (from Manganese Ascorbate)	3 mg	150%*
High Purity FCHG49 <sup>®</sup> Glucosamine HCl	500 mg	†
TRH122 <sup>®</sup> Sodium Chondroitin Sulfate (Contains approximately 8% moisture)	400 mg	†

\*Percent Daily Values are based on a 2,000 calorie diet

†Daily Value Not Established

Ingredients: Glucosamine hydrochloride (crab and shrimp\*\*), sodium chondroitin sulfate, manganese ascorbate, gelatin, water, magnesium stearate, titanium dioxide, FD&C Red No. 3, and FD&C Blue No. 1.

\*\*Derived from crab and shrimp.

^Source: SLACK Incorporated Market Research Survey, April 2009. Survey conducted of Orthopedic Specialists relating to glucosamine/chondroitin sulfate brands.

Cosamin<sup>®</sup> DS contains FCHG49<sup>®</sup> Glucosamine and TRH122<sup>™</sup> Sodium Chondroitin Sulfate, Nutramax Laboratories<sup>™</sup> exclusive proprietary researched specifications.

U.S. Patent No. 5,587,363

© 2011 Nutramax Laboratories, Inc.

**nutramax**<sup>™</sup>  
LABORATORIES, INC.

2208 Lakeside Boulevard • Edgewood, MD 21040  
nutramaxlabs.com • 1-800-299-6167

One bottle can last up to 72 days  
when taking 1 capsule daily on a long-term basis

**SUGGESTED USE:**

May be taken once daily or throughout the day

Initial 1-2 months	3 Capsules Per Day
Economical Long-term	1-2 Capsules Per Day

Exclusive Formula •  
**Cosamin<sup>®</sup>DS**  
JOINT HEALTH SUPPLEMENT

*Works Better. Lasts Longer.<sup>®</sup>*

Safe and Economical:

- there are no known interactions or serious side effects with Cosamin DS
- exclusive formula allows reduction in the number of capsules taken over time



Tested and Certified  
by NSF

If you have any condition or allergy that requires medical attention, you should always consult your physician before taking any drug or dietary supplement.

Cosamin<sup>®</sup>DS is a product of  
Nutramax Laboratories



THE #1 BRAND RECOMMENDED  
BY ORTHOPEDIC SPECIALISTS\*

Exclusive Formula •  
**Cosamin<sup>®</sup>DS**  
JOINT HEALTH SUPPLEMENT

THE ORIGINAL RESEARCHED BRAND

# EXHIBIT B



701 B Street, Suite 1700 | San Diego, CA 92101

T | 619.338.1100 F | 619.338.1101

www.bholaw.com

Timothy G. Blood  
tblood@bholaw.com

April 11, 2013

**VIA CERTIFIED MAIL (RETURN RECEIPT)**  
**(RECEIPT NO. 7005 0390 0005 9156 4954)**

Mr. Bob Henderson  
President  
Nutramax Laboratories, Inc.  
2208 Lakeside Boulevard  
Edgewood, Maryland 21040

Re: *Dorfman v. Nutramax Laboratories, Inc., et al.*

Dear Mr. Henderson:

We represent Robert Dorfman (“Plaintiff”) and all other consumers similarly situated in an action against Nutramax Laboratories, Inc. (“Nutramax”), Wal-Mart Stores, Inc., and Rite-Aid Corporation (collectively “Defendants”), arising out of, *inter alia*, misrepresentations related to joint health and cartilage health benefits either express or implied, to consumers about the efficacy and benefits of the Cosamin DS and Cosamin ASU line of joint dietary supplements, including but not limited to the following statements:

- Protect your cartilage with the ONLY BRAND proven to reduce joint pain;
- Shown in laboratory tests to PROTECT CARTILAGE cells from breakdown;
- The ONLY brand proven effective in controlled, published U.S. clinical studies to reduce joint pain; and
- Cosamin DS is the #1 Brand Recommended by Orthopedic Specialists. As a joint health supplement, Cosamin DS helps reduce joint pain and stiffness by using ingredients that are safe, effective, and easily absorbed. Cosamin DS is superior to all other brands and has been proven effective in published clinical studies.

Plaintiff and others similarly situated purchased the Cosamin products unaware of the fact that Defendants’ representations were false and deceptive, including because properly conducted studies demonstrate that the Cosamin products are ineffective, and there is otherwise no adequate scientific or clinical proof that the Cosamin products provide the purported major health benefits to all persons. The full claims, including the facts and circumstances surrounding these claims, are detailed in the Class Action Complaint, a copy of which is attached and incorporated by this reference.

These representations and omissions are false and misleading and constitute unfair methods of competition and unlawful, unfair, and fraudulent acts or practices, undertaken by



Mr. Bob Henderson  
April 11, 2013  
Page 2

defendant with the intent to result in the sale of the Cosamin products to the consuming public. The joint protection, mobility, pain reduction and comfort representations do not assist consumers; they simply mislead them.

These practices constitute violations of the Consumers Legal Remedies Act, California Civil Code §1750 *et seq.* Specifically, Defendants' practices violate California Civil Code §1770(a) under, *inter alia*, the following subdivisions:

(5) Representing that goods or services have . . . approval, characteristics, . . . uses [or] benefits . . . which they do not have . . . .

\* \* \*

(7) Representing that goods or services are of a particular standard, quality or grade . . . if they are of another.

\* \* \*

(9) Advertising goods or services with intent not to sell them as advertised.

\* \* \*

(16) Representing that the subject of a transaction has been supplied in accordance with a previous representation when it has not.

As detailed in the attached Complaint, Defendants' practices also violate California Business and Professions Code §17200 *et seq.*, and constitute a breach of warranty.

While the Complaint constitutes sufficient notice of the claims asserted, pursuant to California Civil Code §1782 and California Commercial Code §2607, we hereby demand on behalf of our client and all others similarly situated that Defendants immediately correct and rectify these violations by ceasing the misleading marketing campaign, ceasing dissemination of false and misleading information as described in the enclosed Complaint, and initiating a corrective advertising campaign to re-educate consumers regarding the truth of the products at issue. In addition, Defendants must offer to refund the purchase price to all consumer purchasers of the Cosamin products, plus provide reimbursement for interest, costs, and fees.

We await your response.

Sincerely,

TIMOTHY G. BLOOD

TGB:jk  
Enclosure  
cc: Todd D. Carpenter



701 B Street, Suite 1700 | San Diego, CA 92101  
T | 619.338.1100 F | 619.338.1101  
www.bholaw.com

Timothy G. Blood  
tblood@bholaw.com

April 11, 2013

**VIA CERTIFIED MAIL (RETURN RECEIPT)**  
**(RECEIPT NO. 7005 0390 0005 9156 4947)**

Mr. Michael T. Duke  
President and CEO  
Wal-Mart Stores, Inc.  
702 SW 8<sup>th</sup> Street  
Bentonville, AR 72716-8611

Re: *Dorfman v. Nutramax Laboratories, Inc., et al.*

Dear Mr. Duke:

We represent Robert Dorfman (“Plaintiff”) and all other consumers similarly situated in an action against Nutramax Laboratories, Inc. (“Nutramax”), Wal-Mart Stores, Inc., and Rite-Aid Corporation (collectively “Defendants”), arising out of, *inter alia*, misrepresentations related to joint health and cartilage health benefits either express or implied, to consumers about the efficacy and benefits of the Cosamin DS and Cosamin ASU line of joint dietary supplements, including but not limited to the following statements:

- The tablets greatly help in protecting your damaged cartilage, thereby help reduce stiffness in your joints.
- Highly recommended by orthopedic surgeons and rheumatologists, these capsules help maintain healthy and pain-free bone joints.
- Orthopedic surgeon and Rheumatologist recommended
- Contains the exclusive chondroitin sulfate selected by the National Institutes of Health for the GAIT study
- Take this Cosamin DS Joint Health Supplement to support your joint health. These Cosamin DS capsules are the only brand that contains pharmaceutical-grade TRH122 chondroitin sulfate and FCHG49 glucosamine. This is why these glucosamine chondroitin supplements from Cosamin DS are a recommended brand from orthopedic surgeons and rheumatologists. This joint health supplement isn't only effective, but it comes in easy-to-swallow capsules, as well
- Supports joint health
- Only brand that contains pharmaceutical-grade TRH122 chondroitin sulfate and FCHG49 glucosamine

Plaintiff and others similarly situated purchased the Cosamin products unaware of the fact that Defendants’ representations were false and deceptive, including because properly conducted studies demonstrate that the Cosamin products are ineffective, and there is otherwise



Mr. Michael T. Duke  
April 11, 2013  
Page 2

no adequate scientific or clinical proof that the Cosamin products provide the purported major health benefits to all persons. The full claims, including the facts and circumstances surrounding these claims, are detailed in the Class Action Complaint, a copy of which is attached and incorporated by this reference.

These representations and omissions are false and misleading and constitute unfair methods of competition and unlawful, unfair, and fraudulent acts or practices, undertaken by defendant with the intent to result in the sale of the Cosamin products to the consuming public. The joint protection, mobility, pain reduction and comfort representations do not assist consumers; they simply mislead them.

These practices constitute violations of the Consumers Legal Remedies Act, California Civil Code §1750 *et seq.* Specifically, Defendants' practices violate California Civil Code §1770(a) under, *inter alia*, the following subdivisions:

- (5) Representing that goods or services have . . .approval, characteristics, . . . uses [or] benefits . . . which they do not have . . . .  
\* \* \*
- (7) Representing that goods or services are of a particular standard, quality or grade . . . if they are of another.  
\* \* \*
- (9) Advertising goods or services with intent not to sell them as advertised.  
\* \* \*
- (16) Representing that the subject of a transaction has been supplied in accordance with a previous representation when it has not.

As detailed in the attached Complaint, Defendants' practices also violate California Business and Professions Code §17200 *et seq.*, and constitute a breach of warranty.

While the Complaint constitutes sufficient notice of the claims asserted, pursuant to California Civil Code §1782 and California Commercial Code §2607, we hereby demand on behalf of our client and all others similarly situated that Defendants immediately correct and rectify these violations by ceasing the misleading marketing campaign, ceasing dissemination of false and misleading information as described in the enclosed Complaint, and initiating a corrective advertising campaign to re-educate consumers regarding the truth of the products at issue. In addition, Defendants must offer to refund the purchase price to all consumer purchasers of the Cosamin products, plus provide reimbursement for interest, costs, and fees.





Mr. Michael T. Duke  
April 11, 2013  
Page 3

We await your response.

Sincerely,

TIMOTHY G. BLOOD

TGB:jk  
Enclosure

cc: Todd D. Carpenter



701 B Street, Suite 1700 | San Diego, CA 92101  
T | 619.338.1100 F | 619.338.1101  
www.bholaw.com

Timothy G. Blood  
tblood@bholaw.com

April 11, 2013

**VIA CERTIFIED MAIL (RETURN RECEIPT)**  
**(RECEIPT NO. 7005 0390 0005 9156 4923)**

Mr. John T. Stanley  
Chairman, President and CEO  
Rite-Aid Corporation  
30 Hunter Lane  
Camp Hill, PA 17011

Re: *Dorfman v. Nutramax Laboratories, Inc., et al.*

Dear Mr. Stanley:

We represent Robert Dorfman (“Plaintiff”) and all other consumers similarly situated in an action against Nutramax Laboratories, Inc. (“Nutramax”), Wal-Mart Stores, Inc., and Rite-Aid Corporation (collectively “Defendants”), arising out of, *inter alia*, misrepresentations related to joint health and cartilage health benefits either express or implied, to consumers about the efficacy and benefits of the Cosamin DS and Cosamin ASU line of joint dietary supplements, including but not limited to the following statements:

- Premium dietary supplement for joint health
- Joint Health Supplement. Exclusive Formula.
- Protect your cartilage with the only brand proven to reduce joint pain.
- The No. 1 brand recommended by orthopedic specialists.
- Helps your joints last longer.
- Cosamin DS is recommended by Doctors and Pharmacists for joint health.
- The only brand proven effective in controlled, published U.S. studies to reduce joint pain.
- Shown in laboratory tests to protect cartilage from breakdown.
- Contains the full clinical strength of active ingredients-compare to other brands,
- Manufactured in the United States following standards practiced by the pharmaceutical industry.
- Tested and certified by NSF.
- The original researched brand.
- Cosamin DS contains FCHG49 Glucosamine and TRH122 sodium chondroitin sulfate, Nutramax Laboratories exclusive proprietary researched specifications.
- Shown to work better than the combination of glucosamine + chondroitin sulfate (In laboratory cell culture studies of inflammatory markers associated with joint



Mr. John T. Stanley  
April 11, 2013  
Page 2

discomfort and cartilage breakdown, it was found that the combination of ASU [avocado/soybean/unsaponifiables] + glucosamine + chondroitin sulfate was better than the combination of glucosamine + chondroitin sulfate in reducing these markers).

Plaintiff and others similarly situated purchased the Cosamin products unaware of the fact that Defendants' representations were false and deceptive, including because properly conducted studies demonstrate that the Cosamin products are ineffective, and there is otherwise no adequate scientific or clinical proof that the Cosamin products provide the purported major health benefits to all persons. The full claims, including the facts and circumstances surrounding these claims, are detailed in the Class Action Complaint, a copy of which is attached and incorporated by this reference.

These representations and omissions are false and misleading and constitute unfair methods of competition and unlawful, unfair, and fraudulent acts or practices, undertaken by defendant with the intent to result in the sale of the Cosamin products to the consuming public. The joint protection, mobility, pain reduction and comfort representations do not assist consumers; they simply mislead them.

These practices constitute violations of the Consumers Legal Remedies Act, California Civil Code §1750 *et seq.* Specifically, Defendants' practices violate California Civil Code §1770(a) under, *inter alia*, the following subdivisions:

- (5) Representing that goods or services have . . .approval, characteristics, . . . uses [or] benefits . . . which they do not have . . . .  
\* \* \*
- (7) Representing that goods or services are of a particular standard, quality or grade . . . if they are of another.  
\* \* \*
- (9) Advertising goods or services with intent not to sell them as advertised.  
\* \* \*
- (16) Representing that the subject of a transaction has been supplied in accordance with a previous representation when it has not.

As detailed in the attached Complaint, Defendants' practices also violate California Business and Professions Code §17200 *et seq.*, and constitute a breach of warranty.

While the Complaint constitutes sufficient notice of the claims asserted, pursuant to California Civil Code §1782 and California Commercial Code §2607, we hereby demand on behalf of our client and all others similarly situated that Defendants immediately correct and rectify these violations by ceasing the misleading marketing campaign, ceasing dissemination of false and misleading information as described in the enclosed Complaint, and initiating a



Mr. John T. Stanley  
April 11, 2013  
Page 3

corrective advertising campaign to re-educate consumers regarding the truth of the products at issue. In addition, Defendants must offer to refund the purchase price to all consumer purchasers of the Cosamin products, plus provide reimbursement for interest, costs, and fees.

We await your response.

Sincerely,

TIMOTHY G. BLOOD

TGB:jk  
Enclosure

cc: Todd D. Carpenter

1 BLOOD HURST & O'REARDON, LLP  
2 TIMOTHY G. BLOOD (149343)  
3 THOMAS J. O'REARDON II (247952)  
4 701 B Street, Suite 1700  
5 San Diego, CA 92101  
6 Telephone: (619) 338-1100  
7 Facsimile: (619) 338-1101  
8 tblood@bholaw.com  
9 toreardon@bholaw.com

6 CARPENTER LAW GROUP  
7 TODD D. CARPENTER (234464)  
8 402 West Broadway, 29th Floor  
9 San Diego, California 92101  
10 Telephone: 619/347-3517  
11 619/756-6991 (fax)

Attorneys for Plaintiff and the Class

11 **UNITED STATES DISTRICT COURT**  
12 **SOUTHERN DISTRICT OF CALIFORNIA**

13 ROBERT DORFMAN, On Behalf of  
14 Himself and All Others Similarly  
15 Situated,

Plaintiff,

v.

17 NUTRAMAX LABORATORIES,  
18 INC., WAL-MART STORES, INC.,  
19 and RITE-AID CORPORATION,

Defendants.

Case No.: '13CV0873 WQHRBB

CLASS ACTION

**AFFIDAVIT OF TODD D.  
CARPENTER PURSUANT TO  
CALIFORNIA CIVIL CODE  
§1780(d)**

1 I, TODD D. CARPENTER, declare as follows:

2 1. I am an attorney duly licensed to practice before all of the courts of  
3 the State of California. I am the principle and owner of the Carpenter Law  
4 Group, and one of the counsel of record for plaintiff in the above-entitled action.

5 2. Defendants Nutramax Laboratories, Inc., Wal-Mart Stores, Inc. and  
6 Rite-Aid Corporation have done and are doing business in the Southern District  
7 of California. Such business includes the marketing and sale of the Cosamin  
8 joint health supplement products at issue. Furthermore, Plaintiff Dorfman  
9 purchased the products in Del Mar, California, and San Diego, California.

10 I declare under penalty of perjury under the laws of the State of California  
11 that the foregoing is true and correct. Executed this 11th day of April, 2013, at  
12 San Diego, California.

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

*/s/ Todd D. Carpenter*  
\_\_\_\_\_  
TODD D. CARPENTER

JS 44 (Rev. 12/12)

### CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

<p><b>I. (a) PLAINTIFFS</b>                  ROBERT DORFMAN, On Behalf of Himself and All Others Similarly Situated</p> <p>(b) County of Residence of First Listed Plaintiff <u>San Diego County, CA</u>                  (EXCEPT IN U.S. PLAINTIFF CASES)</p> <p>(c) Attorneys (Firm Name, Address, and Telephone Number)                  BLOOD HURST &amp; O'REARDON, LLP                  Timothy G. Blood (149343)                  701 B Street, Suite 1700, San Diego, CA 92101 Tel: 619-338-1100</p>	<p><b>DEFENDANTS</b>                  NUTRAMAX LABORATORIES, INC. WAL-MART STORES, INC., and RITE-AID CORPORATION</p> <p>County of Residence of First Listed Defendant <u>Harford County, MD</u>                  (IN U.S. PLAINTIFF CASES ONLY)</p> <p>NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.</p> <p>Attorneys (If Known)</p> <p style="text-align: center; font-size: 1.2em;"><b>'13CV0873 WQHRBB</b></p>
--	--

<p><b>II. BASIS OF JURISDICTION</b> (Place an "X" in One Box Only)</p> <p><input type="checkbox"/> 1 U.S. Government Plaintiff</p> <p><input checked="" type="checkbox"/> 3 Federal Question (U.S. Government Not a Party)</p> <p><input type="checkbox"/> 2 U.S. Government Defendant</p> <p><input type="checkbox"/> Diversity (Indicate Citizenship of Parties in Item III)</p>	<p><b>III. CITIZENSHIP OF PRINCIPAL PARTIES</b> (Place an "X" in One Box for Plaintiff and One Box for Defendant)</p> <table style="width:100%; border-collapse: collapse;"> <thead> <tr> <th></th> <th>PTF</th> <th>DEF</th> <th></th> <th>PTF</th> <th>DEF</th> </tr> </thead> <tbody> <tr> <td>Citizen of This State</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>Incorporated or Principal Place of Business in This State</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Citizen of Another State</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>Incorporated and Principal Place of Business in Another State</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Citizen or Subject of a Foreign Country</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>Foreign Nation</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		PTF	DEF		PTF	DEF	Citizen of This State	<input type="checkbox"/>	<input type="checkbox"/>	Incorporated or Principal Place of Business in This State	<input type="checkbox"/>	<input type="checkbox"/>	Citizen of Another State	<input type="checkbox"/>	<input type="checkbox"/>	Incorporated and Principal Place of Business in Another State	<input type="checkbox"/>	<input type="checkbox"/>	Citizen or Subject of a Foreign Country	<input type="checkbox"/>	<input type="checkbox"/>	Foreign Nation	<input type="checkbox"/>	<input type="checkbox"/>
	PTF	DEF		PTF	DEF																				
Citizen of This State	<input type="checkbox"/>	<input type="checkbox"/>	Incorporated or Principal Place of Business in This State	<input type="checkbox"/>	<input type="checkbox"/>																				
Citizen of Another State	<input type="checkbox"/>	<input type="checkbox"/>	Incorporated and Principal Place of Business in Another State	<input type="checkbox"/>	<input type="checkbox"/>																				
Citizen or Subject of a Foreign Country	<input type="checkbox"/>	<input type="checkbox"/>	Foreign Nation	<input type="checkbox"/>	<input type="checkbox"/>																				

**IV. NATURE OF SUIT** (Place an "X" in One Box Only)

<p><b>CONTRACT</b></p> <p><input type="checkbox"/> 110 Insurance</p> <p><input type="checkbox"/> 120 Marine</p> <p><input type="checkbox"/> 130 Miller Act</p> <p><input type="checkbox"/> 140 Negotiable Instrument</p> <p><input type="checkbox"/> 150 Recovery of Overpayment &amp; Enforcement of Judgment</p> <p><input type="checkbox"/> 151 Medicare Act</p> <p><input type="checkbox"/> 152 Recovery of Defaulted Student Loans (Excludes Veterans)</p> <p><input type="checkbox"/> 153 Recovery of Overpayment of Veteran's Benefits</p> <p><input type="checkbox"/> 160 Stockholders' Suits</p> <p><input type="checkbox"/> 190 Other Contract</p> <p><input type="checkbox"/> 195 Contract Product Liability</p> <p><input type="checkbox"/> 196 Franchise</p>	<p><b>PERSONAL INJURY</b></p> <p><input type="checkbox"/> 310 Airplane</p> <p><input type="checkbox"/> 315 Airplane Product Liability</p> <p><input type="checkbox"/> 320 Assault, Libel &amp; Slander</p> <p><input type="checkbox"/> 330 Federal Employers' Liability</p> <p><input type="checkbox"/> 340 Marine</p> <p><input type="checkbox"/> 345 Marine Product Liability</p> <p><input type="checkbox"/> 350 Motor Vehicle</p> <p><input type="checkbox"/> 355 Motor Vehicle Product Liability</p> <p><input type="checkbox"/> 360 Other Personal Injury</p> <p><input type="checkbox"/> 362 Personal Injury - Medical Malpractice</p>	<p><b>PERSONAL INJURY</b></p> <p><input type="checkbox"/> 365 Personal Injury - Product Liability</p> <p><input type="checkbox"/> 367 Health Care/Pharmaceutical Personal Injury Product Liability</p> <p><input type="checkbox"/> 368 Asbestos Personal Injury Product Liability</p> <p><b>PERSONAL PROPERTY</b></p> <p><input type="checkbox"/> 370 Other Fraud</p> <p><input type="checkbox"/> 371 Truth in Lending</p> <p><input type="checkbox"/> 380 Other Personal Property Damage</p> <p><input type="checkbox"/> 385 Property Damage Product Liability</p>	<p><b>FORFEITURE/PENALTY</b></p> <p><input type="checkbox"/> 625 Drug Related Seizure of Property 21 USC 881</p> <p><input type="checkbox"/> 690 Other</p> <p><b>LABOR</b></p> <p><input type="checkbox"/> 710 Fair Labor Standards Act</p> <p><input type="checkbox"/> 720 Labor/Management Relations</p> <p><input type="checkbox"/> 740 Railway Labor Act</p> <p><input type="checkbox"/> 751 Family and Medical Leave Act</p> <p><input type="checkbox"/> 790 Other Labor Litigation</p> <p><input type="checkbox"/> 791 Employee Retirement Income Security Act</p> <p><b>IMMIGRATION</b></p> <p><input type="checkbox"/> 462 Naturalization Application</p> <p><input type="checkbox"/> 465 Other Immigration Actions</p>	<p><b>BANKRUPTCY</b></p> <p><input type="checkbox"/> 422 Appeal 28 USC 158</p> <p><input type="checkbox"/> 423 Withdrawal 28 USC 157</p> <p><b>PROPERTY RIGHTS</b></p> <p><input type="checkbox"/> 820 Copyrights</p> <p><input type="checkbox"/> 830 Patent</p> <p><input type="checkbox"/> 840 Trademark</p> <p><b>SOCIAL SECURITY</b></p> <p><input type="checkbox"/> 861 HIA (1395ff)</p> <p><input type="checkbox"/> 862 Black Lung (923)</p> <p><input type="checkbox"/> 863 DIWC/DIWW (405(g))</p> <p><input type="checkbox"/> 864 SSID Title XVI</p> <p><input type="checkbox"/> 865 RSI (405(g))</p> <p><b>FEDERAL TAX SUITS</b></p> <p><input type="checkbox"/> 870 Taxes (U.S. Plaintiff or Defendant)</p> <p><input type="checkbox"/> 871 IRS--Third Party 26 USC 7609</p>	<p><b>OTHER STATUTES</b></p> <p><input type="checkbox"/> 375 False Claims Act</p> <p><input type="checkbox"/> 400 State Reapportionment</p> <p><input type="checkbox"/> 410 Antitrust</p> <p><input type="checkbox"/> 430 Banks and Banking</p> <p><input type="checkbox"/> 450 Commerce</p> <p><input type="checkbox"/> 460 Deportation</p> <p><input type="checkbox"/> 470 Racketeer Influenced and Corrupt Organizations</p> <p><input type="checkbox"/> 480 Consumer Credit</p> <p><input type="checkbox"/> 490 Cable/Sat TV</p> <p><input type="checkbox"/> 850 Securities/Commodities/Exchange</p> <p><input checked="" type="checkbox"/> 890 Other Statutory Actions</p> <p><input type="checkbox"/> 891 Agricultural Acts</p> <p><input type="checkbox"/> 893 Environmental Matters</p> <p><input type="checkbox"/> 895 Freedom of Information Act</p> <p><input type="checkbox"/> 896 Arbitration</p> <p><input type="checkbox"/> 899 Administrative Procedure Act/Review or Appeal of Agency Decision</p> <p><input type="checkbox"/> 950 Constitutionality of State Statutes</p>
---	---	---	---	--	---

**V. ORIGIN** (Place an "X" in One Box Only)

1 Original Proceeding     2 Removed from State Court     3 Remanded from Appellate Court     4 Reinstated or Reopened     5 Transferred from Another District (specify)     6 Multidistrict Litigation

**VI. CAUSE OF ACTION**

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity):  
28 USC section 1332(d)(2)


Brief description of cause:  
Violations of UCL, CLRA, express warranty, etc.

**VII. REQUESTED IN COMPLAINT:**

CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P.    DEMAND \$ 5,000,000.00    CHECK YES only if demanded in complaint: JURY DEMAND:  Yes     No

**VIII. RELATED CASE(S) IF ANY** (See instructions):

JUDGE \_\_\_\_\_ DOCKET NUMBER \_\_\_\_\_

DATE 04/11/2013    SIGNATURE OF ATTORNEY OF RECORD 

**FOR OFFICE USE ONLY**

RECEIPT # \_\_\_\_\_ AMOUNT \_\_\_\_\_ APPLYING IFP \_\_\_\_\_ JUDGE \_\_\_\_\_ MAG. JUDGE \_\_\_\_\_